Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.

Abstract

The current cure rate of 80% in childhood acute lymphoblastic leukemia (ALL) attests to the effectiveness of risk-directed therapy developed through well-designed clinical trials. The ongoing Total Therapy Study XV at St. Jude Children's Research Hospital was designed to further increase cure rate and to improve quality of life. The study consists of… (More)

Topics

Cite this paper

@article{Pui2004RationaleAD, title={Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.}, author={C. H. Pui and M V Relling and John T. Sandlund and J. R. Downing and Dario Campana and W. E. Evans}, journal={Annals of hematology}, year={2004}, volume={83 Suppl 1}, pages={S124-6} }